Europe Losing Ground in Bioengineering Innovation Race
For decades, European life sciences have been a quiet powerhouse. The sector contributes €1.5 trillion to the region’s economy and supports 29 million jobs. [2] Yet beneath that success lies a troubling reality: the European Union is losing ground in bioengineering, one of the most innovation-intensive fields in modern medicine. The gap is not subtle. It is structural, measurable, and widening with each passing year.
Bioengineering sits at the intersection of mathematics, computation, engineering, and biomedicine. It produces the tools that make modern medicine possible - artificial intelligence that predicts protein structures, rapid genome sequencing for precision medicine, and the technologies behind cutting-edge cell therapies. These are not abstract concepts. They are the practical engines of tomorrow’s healthcare. And Europe is failing to build them at scale.
The numbers paint a stark picture. The EU’s 27 member states host fewer than ten fully autonomous bioengineering departments. [1] The United States and China each have more than one hundred. Not a single EU27 university made the 2025 ShanghaiRanking’s top-30 list of biomedical engineering departments. Eighteen institutions from Asia did. The investment gap follows the same trajectory: in 2023, European biotechnology companies attracted $11.5 billion in funding, compared with roughly $57 billion in the United States and $21 billion in China. [1]
This is not a problem that can be ignored. The technologies bioengineering produces are becoming the backbone of precision medicine, regenerative therapies, and diagnostic innovation. Every year the gap persists, Europe’s position in global biomedicine weakens further. The question is no longer whether Europe has a problem, but whether it can still fix it before the gap becomes permanent.
The Data That Demands a Reckoning
The structural disadvantage becomes visible when comparing how other nations organize their research. The United States, China, Switzerland, and the United Kingdom all recognize bioengineering as a strategic priority. They fund it accordingly. They build departments around it. They treat it as a discipline worthy of dedicated institutional structures. The European Union has not yet caught on.
Compare the institutional landscape directly. The EU27 hosts fewer than ten fully autonomous bioengineering departments. The United States and China each exceed one hundred. That is not a marginal difference. It is an order of magnitude. When an entire field of research has ten times fewer dedicated academic homes, the consequences ripple through every downstream outcome - trained researchers, funded projects, commercial spin-offs, clinical applications.
The financial gap reinforces the institutional one. In 2023, biotechnology companies in Europe attracted $11.5 billion in funding. The United States drew approximately $57 billion. China secured $21 billion. Europe is not merely behind - it is outspent by a factor of five compared with the United States, and by nearly double compared with China. Money alone does not guarantee innovation, but without it, even the best ideas struggle to become working technologies.
These numbers demand an explanation that goes beyond talent or creativity. Europe has no shortage of brilliant scientists. Its life-sciences sector is among the strongest in the world. The gap is not about individual capability. It is about systemic priorities - where funding flows, how institutions are structured, and whether bioengineering is treated as a core discipline or an afterthought.
The consequence is already visible in global rankings. The 2025 ShanghaiRanking placed no EU27 university in the top-30 list of biomedical engineering departments. [1] Eighteen Asian institutions made the cut. This is not a snapshot of a single bad year. It is the accumulated result of years of underinvestment and institutional neglect, now measurable in concrete outcomes.
The Gathering Response From Heidelberg
In March, 25 specialists from around the world gathered at the European Molecular Biology Organization in Heidelberg, Germany, to confront this widening gap. [2] The group included Vasilis Ntziachristos, chair of biological imaging at the Technical University of Munich and director of bioengineering at Helmholtz Munich. [3] Thomas Schwarz-Romond, administrative director at Helmholtz Munich’s Pioneer Campus, joined as well. [4] Fiona M. Watt, director of the European Molecular Biology Organization, was among the participants. [2]
The group’s message is direct: they call on the European Council and relevant EU directorates to adopt a European bioengineering agenda built on three themes. The proposal names specific institutions and specific actions, asking for structural change rather than cosmetic adjustments.
The timing matters. Europe still has assets to build on. Its life-sciences sector is vibrant and economically significant. The region has a strong culture of collaborative research, academic-industry partnerships, and funding programmes that encourage technology development. For decades, Europe has excelled in other engineering disciplines - from civil to computational. The infrastructure for excellence exists. It has simply not been applied to bioengineering with the same intensity.
Europe’s open society, social-security systems, healthcare, and education infrastructures also attract global talent. That is a genuine competitive advantage. Researchers from around the world want to work in environments that combine scientific freedom with social stability. Europe offers both. But talent alone cannot compensate for missing institutional structures and chronic underfunding.
The Heidelberg group argues that these strengths can be leveraged. The EU can build on its life-sciences sector while closing the bioengineering gap. The three themes they propose are designed to do exactly that - to convert Europe’s existing advantages into a coherent bioengineering strategy. The proposal is now on the table, backed by specialists who understand both the problem and the path forward. Whether the European Council acts on it will determine whether Europe can reverse its decline in this critical field.
Sources
1. DOI: 10.1038/d41586-026-02389-5
2. European Molecular Biology Organization